Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares ESG Aware 60/40 Balanced Allocation ETF (NY:EAOR)

34.22 -0.02 (-0.06%)
Streaming Delayed Price Updated: 9:30 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares ESG Aware 60/40 Balanced Allocation ETF

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided
Via Stocktwits
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Via Stocktwits
Inspire Medical Systems Stock Slumps On Downgrades, Price Target Cuts: Retail Believes Stock Is Way Oversold
Via Stocktwits
CVS Health CFO Says Company Maintaining Prudent View On Medical Cost Trends Through Remainder Of Year
The firm now expects full-year adjusted earnings per share of $6.30 to $6.40, up from its previous guidance of $6.00 to $6.20. 
Via Stocktwits
Topics Artificial Intelligence Earnings Workforce
Why Did Sarepta Stock Jump 20% On Tuesday? Here’s What JPMorgan, Bernstein, Barclays Said About Elevidys
JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target. 
Via Stocktwits
Topics Death
Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier
Via Stocktwits
Moderna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And Older
The vaccine was previously available for pediatric populations under Emergency Use Authorization only. 
Via Stocktwits
Organon Drops Drug Development For Endometriosis Pain After Mid-Stage Study Fails To Show Results
Organon said that the mid-stage study evaluating its OG-6219 in endometriosis-related pain did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to... 
Via Stocktwits
Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trial
The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate. 
Via Stocktwits
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.